Pharmaceutical companies GlaxoSmithKline (GSK) and Sanofi join the race to discover a Covid-19 vaccine, clinical trials this week.
Pharmaceutical giants have recruited more than 400 people for the phase one and two trial, which will assess the protection of the candidate vaccine.
The BRITISH government signed an agreement with corporations in July for 60 million doses – rumoured to be 500 million pounds – in the hope that it will be a success.
Initial results, at 11 sites in the United States, are expected in early December, and Phase 3 will begin before the end of 2020.
The Department of Business, Energy and Industrial Strategy had said in the past that the blow could be hit by high-risk Britons early next year if it passes the tests.
GSK and Sanofi in combination have the highest vaccine production capacity in the world and their injection has the “potential to succeed over the pandemic” that has already killed 863,000 people.
The vaccine, one of 34 recently found in clinical trials, is based on the existing DNA generation used to produce Sanofi’s seasonal influenza vaccine.
If all vaccines ordered in advance across the UK are successful and go into production, the country will have a large inventory of 340 million vaccines, enough to give each and every user in the country five each.
French drug manufacturer Sanofi and its British counterpart GSK have recruited more than 400 people in the United States for phase one and two trial, which will assess the protection of the candidate vaccine.
Roger Connor, president of London-based GSK Vaccines, said: “We believe this adjuvant vaccine candidate has the potential to play a vital role in overcoming the Covid-19 pandemic, both in the UK and around the world.”
Roger Connor, president of GSK Vaccines, said: “The transition from this vaccine to clinical progression is a moment in progress toward the global pandemic we all face.
This is based on the trust already demonstrated through governments in this protein-based adjuvant candidate vaccine, which uses the established generation of any of the companies and can be produced on a large scale through two of the world’s leading vaccine manufacturers.
By posting your comment, you agree to our space rules.
We will post your comment and link to the story on your Facebook timeline at the same time as it will be posted on MailOnline.To do this, we will link your MailOnline account to your Facebook account.We’ll ask you to check this for your first Facebook post.
You can use each post if you need it to be published on Facebook.Your facebook core points will be used to provide you with personalized content, marketing and advertising in accordance with our privacy policy.
Edited via Associated Newspapers Ltd
Part of the Daily Mail, The Mail on Sunday and Metro Media Group